Immunohistochemical distinction between intrahepatic cholangiocarcinoma and pancreatic ductal adenocarcinoma

Human Pathology

Volumn 45, Issue 2, 2014, Pages 394-400

  Lok, Terry ^a   Chen, Lihong ^a,b   Lin, Fan ^c   Wang, Hanlin L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b FUJIAN MEDICAL UNIVERSITY   (China)

^c GEISINGER MEDICAL CENTER   (United States)

Author keywords

CK17; IMP3; Intrahepatic cholangiocarcinoma; Maspin; MUC5AC; Pancreatic ductal adenocarcinoma; pVHL; S100P

Indexed keywords

CYTOKERATIN 17; INSULIN LIKE GROWTH FACTOR 2 MESSENGER RNA BINDING PROTEIN 3; MASPIN; MUCIN 5AC; PROTEIN S 100; RNA BINDING PROTEIN; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; COMPARATIVE STUDY; DIAGNOSTIC VALUE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIVER BIOPSY; MAJOR CLINICAL STUDY; MIDDLE AGED; PANCREAS ADENOCARCINOMA; PANCREAS METASTASIS; PRIMARY TUMOR; PROTEIN EXPRESSION; STAINING; STOMACH MUCOSA; VERY ELDERLY;

CK17; IMP3; INTRAHEPATIC CHOLANGIOCARCINOMA; MASPIN; MUC5AC; PANCREATIC DUCTAL ADENOCARCINOMA; PVHL; S100P;

AGED; AGED, 80 AND OVER; CALCIUM-BINDING PROTEINS; CARCINOMA, PANCREATIC DUCTAL; CHOLANGIOCARCINOMA; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-17; LIVER NEOPLASMS; MIDDLE AGED; MUCIN 5AC; NEOPLASM PROTEINS; PANCREATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 84892700759     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2013.10.004     Document Type: Article

References (31)

1. R.M. Thomas, and S.A. Ahmad Current concepts in the surgical management of pancreatic cancer Surg Oncol Clin N Am 19 2010 335 358
2. J.E. Hooper, T.K. Morgan, and M. Grompe et al. The novel monoclonal antibody HPC2 and N-cadherin distinguish pancreatic ductal adenocarcinoma from cholangiocarcinoma Hum Pathol 43 2012 1583 1589
3. J.T. Ney, H. Zhou, and B. Sipos et al. Podocalyxin-like protein 1 expression is useful to differentiate pancreatic ductal adenocarcinomas from adenocarcinomas of the biliary and gastrointestinal tracts Hum Pathol 38 2007 359 364
4. M.T. Schmidt, E.A. Himmelfarb, H. Shafi, F. Lin, H. Xu, and H.L. Wang Use of IMP3, S100P, and pVHL immunopanel to aid in the interpretation of bile duct biopsies with atypical histology or suspicious for malignancy Appl Immunohistochem Mol Morphol 20 2012 478 487
5. H. Liu, J. Shi, and V. Anandan et al. Reevaluation and identification of the best immunohistochemical panel (pVHL, Maspin, S100P, IMP-3) for ductal adenocarcinoma of the pancreas Arch Pathol Lab Med 136 2012 601 609
6. M. Levy, F. Lin, H. Xu, D. Dhall, B.O. Spaulding, and H.L. Wang S100P, von Hippel-Lindau gene product, and IMP3 serve as a useful immunohistochemical panel in the diagnosis of adenocarcinoma on endoscopic bile duct biopsy Hum Pathol 41 2010 1210 1219
7. F. Lin, J. Shi, and H. Liu et al. Diagnostic utility of S100P and von Hippel-Lindau gene product (pVHL) in pancreatic adenocarcinoma - with implication of their roles in early tumorigenesis Am J Surg Pathol 32 2008 78 91
8. J. Shi, H. Liu, H.L. Wang, J.W. Prichard, and F. Lin Diagnostic utility of von Hippel-Lindau gene product, maspin, IMP3, and S100P in adenocarcinoma of the gallbladder Hum Pathol 44 2013 503 511
9. H. Liu, J. Shi, and H.L. Wang et al. Expression of von Hippel-Lindau gene product (pVHL) and S100P in cystic neoplasms of the pancreas - with an implication for their roles in tumorigenesis Ann Clin Lab Sci 42 2012 109 117
10. H. Deng, J. Shi, M. Wilkerson, S. Meschter, W. Dupree, and F. Lin Usefulness of S100P in diagnosis of adenocarcinoma of pancreas on fine-needle aspiration biopsy specimens Am J Clin Pathol 129 2008 81 88
11. S.Y. Park, S.J. Roh, and Y.N. Kim et al. Expression of MUC1, MUC2, MUC5AC and MUC6 in cholangiocarcinoma: prognostic impact Oncol Rep 22 2009 649 657
12. J. Luttges, G. Zamboni, D. Longnecker, and G. Kloppel The immunohistochemical mucin expression pattern distinguishes different types of intraductal papillary mucinous neoplasms of the pancreas and determines their relationship to mucinous noncystic carcinoma and ductal adenocarcinoma Am J Surg Pathol 25 2001 942 948
13. P.G. Chu, R.E. Schwarz, S.K. Lau, Y. Yen, and L.M. Weiss Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2 Am J Surg Pathol 29 2005 359 367
14. M.J. Lee, H.S. Lee, W.H. Kim, Y. Choi, and M. Yang Expression of mucins and cytokeratins in primary carcinomas of the digestive system Mod Pathol 16 2003 403 410
15. L. Xiong, Z. Yang, L. Yang, J. Liu, and X. Miao Expressive levels of MUC1 and MUC5AC and their clinicopathologic significances in the benign and malignant lesions of gallbladder J Surg Oncol 105 2012 97 103
16. N.S. Goldstein, and D. Bassi Cytokeratins 7, 17, and 20 reactivity in pancreatic and ampulla of Vater adenocarcinomas: percentage of positivity and distribution is affected by the cut-point threshold Am J Clin Pathol 115 2001 695 702
17. T. Becker, V. Gerke, E. Kube, and K. Weber S100P, a novel Ca(2+)-binding protein from human placenta: cDNA cloning, recombinant protein expression and Ca2+ binding properties Eur J Biochem 207 1992 541 547
18. Y. Sato, K. Harada, M. Sasaki, and Y. Nakanuma Clinicopathological significance of S100 protein expression in cholangiocarcinoma J Gastroenterol Hepatol 28 2013 1422 1429
19. S. Hamada, K. Satoh, and M. Hirota et al. Calcium-binding protein S100P is a novel diagnostic marker of cholangiocarcinoma Cancer Sci 102 2011 150 156
20. S. Aishima, N. Fujita, and Y. Mano et al. Different roles of S100P overexpression in intrahepatic cholangiocarcinoma: carcinogenesis of perihilar type and aggressive behavior of peripheral type Am J Surg Pathol 35 2011 590 598
21. J.H. Tsai, W.C. Huang, K.T. Kuo, R.H. Yuan, Y.L. Chen, and Y.M. Jeng S100P immunostaining identifies a subset of peripheral-type intrahepatic cholangiocarcinomas with morphological and molecular features similar to those of perihilar and extrahepatic cholangiocarcinomas Histopathology 61 2012 1106 1116
22. F. Lin, J. Shi, and H. Liu et al. Immunohistochemical detection of the von Hippel-Lindau gene product (pVHL) in human tissues and tumors: a useful marker for metastatic renal cell carcinoma and clear cell carcinoma of the ovary and uterus Am J Clin Pathol 129 2008 592 605
23. H. Hoshi, T. Sawada, and M. Uchida et al. Tumor-associated MUC5AC stimulates in vivo tumorigenicity of human pancreatic cancer Int J Oncol 38 2011 619 627
24. K. Nagata, M. Horinouchi, and M. Saitou et al. Mucin expression profile in pancreatic cancer and the precursor lesions J Hepatobiliary Pancreat Surg 14 2007 243 254
25. J. Luttges, H. Galehdari, and V. Brocker et al. Allelic loss is often the first hit in the biallelic inactivation of the p53 and DPC4 genes during pancreatic carcinogenesis Am J Pathol 158 2001 1677 1683
26. C. Boonla, B. Sripa, and P. Thuwajit et al. MUC1 and MUC5AC mucin expression in liver fluke-associated intrahepatic cholangiocarcinoma World J Gastroenterol 11 2005 4939 4946
27. A.S. Mall, M.G. Tyler, and S.B. Ho et al. The expression of MUC mucin in cholangiocarcinoma Pathol Res Pract 206 2010 805 809
28. S. Aishima, Y. Kuroda, and Y. Nishihara et al. Gastric mucin phenotype defines tumour progression and prognosis of intrahepatic cholangiocarcinoma: gastric foveolar type is associated with aggressive tumour behaviour Histopathology 49 2006 35 44
29. N. Guedj, Q. Zhan, and M. Perigny et al. Comparative protein expression profiles of hilar and peripheral hepatic cholangiocarcinomas J Hepatol 51 2009 93 101
30. M. Sarbia, F. Fritze, H. Geddert, C. von Weyhern, R. Rosenberg, and K. Gellert Differentiation between pancreaticobiliary and upper gastrointestinal adenocarcinomas: is analysis of cytokeratin 17 expression helpful? Am J Clin Pathol 128 2007 255 259
31. H.S. Yang, R. Tamayo, and M. Almonte et al. Clinical significance of MUC1, MUC2 and CK17 expression patterns for diagnosis of pancreatobiliary carcinoma Biotech Histochem 87 2012 126 132